 "Sun Pharma")
India’s largest pharmaceutical (pharma) company, Sun Pharmaceutical Industries, reported a strong revenue performance for the July-September quarter (Q2) of 2025-26 (FY26), driven by key segments and geographies. Better-than-expected margins and lower research and development spending lifted operational performance. With a robust product pipeline and sustained growth momentum across markets, several brokerages have upgraded the stock, while others have maintained their ‘buy’ ratings.
Revenue for the quarter rose 8.6 per cent year-on-year (Y-o-Y), ahead of estimates, led by India (up 11 per cent) and the Rest of the World market (up 23 per cent). The US generics business continues to weigh
